Sheldon Cao

Publications by Year

Research Areas

Microtubule and mitosis dynamics, Vascular Tumors and Angiosarcomas, Cancer-related Molecular Pathways, Chronic Lymphocytic Leukemia Research, HER2/EGFR in Cancer Research

Most-Cited Works

• → TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens(2011)77 cited
• → Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C‐Lock linker(2019)20 cited
• → Development of a bridging ELISA for detection of antibodies against ZV0203 in cynomolgus monkey serum(2022)6 cited
• → Abstract 651: Superior anti-tumor activity compared to T-DM1 in preclinical studies of targeted therapies for her2-positive cancers by a novel her2-ADC ZV0201(2015)2 cited
• → Data from TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens(2023)
• → Supplementary Figure 1 from TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens(2023)
• → Supplementary Figure 2 from TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens(2023)
• → Supplementary Table 1 from TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens(2023)
• → Supplementary Figure 3 from TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens(2023)